Given the increasing popularity and coverage by health insurance policies of incretin-based medications for obesity, most notably glucagon-like peptide 1 (GLP-1) receptor agonists and double GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists, the use of these medications in hypothalamic obesity has increased and they have shown variable results ranging from a stabilization of weight gain to significant weight loss [7]. The gene discussed is GLP1R; the disease is obesity disorder.